Your browser doesn't support javascript.
loading
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.
Mielke, Dieter; Stanfield-Oakley, Sherry; Borate, Bhavesh; Fisher, Leigh H; Faircloth, Katelyn; Tuyishime, Marina; Greene, Kelli; Gao, Hongmei; Williamson, Carolyn; Morris, Lynn; Ochsenbauer, Christina; Tomaras, Georgia; Haynes, Barton F; Montefiori, David; Pollara, Justin; deCamp, Allan C; Ferrari, Guido.
Afiliação
  • Mielke D; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Stanfield-Oakley S; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Borate B; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
  • Fisher LH; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
  • Faircloth K; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Centergrid.270240.3, Seattle, Washington, USA.
  • Tuyishime M; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Greene K; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Gao H; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Williamson C; Department of Surgery, Duke Universitygrid.471396.egrid.26009.3d, Durham, North Carolina, USA.
  • Morris L; Division of Medical Virology, Department of Pathology, University of Cape Towngrid.7836.a, Cape Town, South Africa.
  • Ochsenbauer C; National Health Laboratory Services, Johannesburg, South Africa.
  • Tomaras G; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.
  • Haynes BF; National Health Laboratory Services, Johannesburg, South Africa.
  • Montefiori D; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa.
  • Pollara J; HIV Virology Section, Center for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
  • deCamp AC; MRC Antibody Immunity Research Unit, University of Witwatersrand, Johannesburg, South Africa.
  • Ferrari G; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
J Virol ; 96(2): e0164321, 2022 01 26.
Article em En | MEDLINE | ID: mdl-34730393
Antibody-dependent cellular cytotoxicity (ADCC) has been correlated with reduced risk of human immunodeficiency virus type 1 (HIV-1) infection in several preclinical vaccine trials and in the RV144 clinical trial, indicating that this is a relevant antibody function to study. Given the diversity of HIV-1, the breadth of vaccine-induced antibody responses is a critical parameter to understand if a universal vaccine is to be realized. Moreover, the breadth of ADCC responses can be influenced by different vaccine strategies and regimens, including adjuvants. Therefore, to accurately evaluate ADCC and to compare vaccine regimens, it is important to understand the range of HIV Envelope (Env) susceptibility to these responses. These evaluations have been limited because of the complexity of the assay and the lack of a comprehensive panel of viruses for the assessment of these humoral responses. Here, we used 29 HIV-1 infectious molecular clones (IMCs) representing different Envelope subtypes and circulating recombinant forms to characterize susceptibility to ADCC from antibodies in plasma from infected individuals, including 13 viremic individuals, 10 controllers, and six with broadly neutralizing antibody responses. We found in our panel that ADCC susceptibility of the IMCs in our panel did not cluster by subtype, infectivity, level of CD4 downregulation, level of shedding, or neutralization sensitivity. Using partitioning around medoids (PAM) clustering to distinguish smaller groups of IMCs with similar ADCC susceptibility, we identified nested panels of four to eight IMCs that broadly represent the ADCC susceptibility of the entire 29-IMC panel. These panels, together with reagents developed to specifically accommodate circulating viruses at the geographical sites of vaccine trials, will provide a powerful tool to harmonize ADCC data generated across different studies and to detect common themes of ADCC responses elicited by various vaccines. IMPORTANCE Antibody-dependent cellular cytotoxicity (ADCC) responses were found to correlate with reduced risk of infection in the RV144 trial of the only human HIV-1 vaccine to show any efficacy to date. However, reagents to understand the breadth and magnitude of these responses across preclinical and clinical vaccine trials remain underdeveloped. In this study, we characterize HIV-1 infectious molecular clones encoding 29 distinct Envelope strains (Env-IMCs) to understand factors that impact virus susceptibility to ADCC and use statistical methods to identify smaller nested panels of four to eight Env-IMCs that accurately represent the full set. These reagents can be used as standardized reagents across studies to fully understand how ADCC may affect efficacy of future vaccine studies and how studies differ in the breadth of responses developed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Citotoxicidade Celular Dependente de Anticorpos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Virol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Citotoxicidade Celular Dependente de Anticorpos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Virol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos